ktd

Kocatepe Tıp Dergisi

3061-9904

Afyonkarahisar Sağlık Bilimleri Üniversitesi

Yüzeyel Mesane Tümörlerinde Tanısal ve Prognostik Yeni Belirleyiciler

Güler

Cem

Tüzel

Emre

Şamlı

Murat

Murat Demirbaş

04 01 2006

7 1 1 9 05 08 2015

1999

Kocatepe Tıp Dergisi

Mesane kanseri en sık görülen genito-üriner kanserler arasında yer almaktadır. Hastalığın tanısı sistoskopik inceleme ve transüretral rezeksiyon ile konulmaktadır. Yüzeyel mesane tümörlerinin üçte ikisi tekrarladığından sistoskopi ile yakın izlem yapmak gerekmektedir. Sistoskopik incelemelerin invaziv yapısı ve yüksek maliyeti nedeniyle yüzeyel mesane tümörlü hastalarda hastalığı non-invaziv bir şekilde saptamak amacıyla yeni moleküler belirleyiciler araştırılmaktadır. Bu yeni moleküler tümör belirleyicileri idrar sitolojisinin tanısal duyarlılığını artırarak, hastalığın seyri sırasında rekürren hastalığın non-invaziv şekilde saptanabilmesini olanaklı kılabilirler ve mesane kanserli hastaların tanı ve incelemesinin değişmesine yol açabilirler. Günümüzde hiçbir tümör belirleyicisi %100 doğruluğa sahip değildir. Bu derlemede literatürde yer alan mesane kanseri tanı ve izleminde kullanılan yeni moleküler tümör belirleyicilerinin gözden geçirilmiştir

Mesane kanseri tanı moleküler belirleyiciler

Messing EM. Urothelial tumors of the urinary tract. In Walsh PC, Retik AB, Vaughan ED, Wein AJ (eds), 8. baskı, WB Saunders Co, New York, 2002, cilt 4, s2732-2784.

Quek ML, Sanderson K, Daneshmand S ve ark. New molecular markers for bladder cancer detection. Curr Opin Urol, 2004; 14: 259-264.

Lotan Y, Roehrborn CG. Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: A decision analytical approach. J Urol, 2002; 167: 75-79.

LokeshwarVB, Soloway MS. Current bladder tumor tests: Does their projected utility fulfill clinical necessity. J Uro1, 2001; 165: 1067-1077.

Ramakumar S, Bhuiyan J, Besse JA ve ark. Comparison of screening methods in the detection of bladder caneer. J Uro1, 1999; 161: 388-389.

Pode D, Shapiro A, Wald M ve ark. Noninvasive detection of bladder cancer with the BTA Stat test. J Uro1, 1999; 161: 443-446.

Lokeshwar VB, Schroeder GL, Selzer MG ve ark. Bladder tumor markers for monitoring recurrence anf screening comparison of hyaluronic acid-- hyaluronidase and BTA-Stat tests. Cancer, 2000; 95: 61-72.

Tsihlias J, Grossman HB. The utility of fıbrin/fıbrinogen degradation products in superficial bladder cancer. Urol Clin North Am, 2000; 27: 39-46.

Thomas L, Leyh H, Marberger M ve ark. Multicenter trial of the quantitative BTA-TRAK assay in the detection of bladder cancer. Clin Chem, 1999; 45: 472-477.

Grocela JA, McDougal WS. Utility of nuclear matrix protein (NMP22) in the detection of recurrent bladder cancer. Urol Clin North Am, 2000; 27: 47-51.

Mian C, Lodde M, Haitel A ve ark. Comparison of two qualitative assays, the UBC-Rapid test and the BTA- Stat test, in the diagnosis of urothelial cell carcinoma of the bladder. Urology, 2000; 56: 228-231.

Knudson W. Tumor associated hyaluronan: providing an extracellular matrix that facilitates invasion. Am J Pathol, 1996; 148: 1721-1726.

LokeshwarVB, Obek C, Pham HT ve ark. Urinary hyaluronic acid and hyaluronidase: Markers for bladder cancer detection and evaluation of grade. J Uro1, 2000; 163: 348-356.

LokeshwarVB, Young MJ, Goudarzi G ve ark. Identification of bladder tumor-derived hyaluronidase: Its similarity to HYAL1. Cancer Res, 1999; 59: 4464-4470.

LokeshwarVB, Rubinowicz D, Schroeder GL ve ark. Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. J Biol Chem, 2001, 276: 11922- 11932.

Shariat SF, Casella R, Khoddami SM ve ark. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol, 2004; 171: 626-630.

Ku JH, Kwak C, Lee HS ve ark. Expression of survivin, a novel inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder. J Urol, 2004; 171: 631-635.

Cheng L, Reiter RE, Jin Y ve ark.

Immunocytochemical analysis of prostate stem cell antigen sa an adjunct marker for the detection of urothelial transitional cell carcinoma in voided urine specimens. J Urol, 2003; 169: 2094-2100.

Shariat SF, Monoski MA, Andrews B ve ark. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. Urology, 2003; 61: 1053-1058.

Shariat SF, Casella R, Monoski MA ve ark. The addition of urokinase-type plasminogen activator to urinary nuclear mstrix protein 22 and cytology improves the detection of bladder cancer. J Urol, 2003; 170: 2244-2247.

Okegawa T, Kinjo M, Horie S ve ark. Detection of mucin 7 gene expression in exfoliated cells in the urine from patients with bladder tumor. Urology, 2003; 62: 182-186.

Mian C, Pycha A, Wiener H ve ark. Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. J Urol, 1999; 161: 1486-1489.

Erdem E, Dikmen G, Atsü N ve ark. Telomerase activity in diagnosis bladder cancer. Scand J Urol Nephrol, 2003; 37: 205-209.

Melissourgos N, Kastrinakis NG, Davilas I ve ark. Detection of human telomerase reverse transcriptase mRNA in urine of patients with bladder cancer: evaluation of an emerging tumor marker. Urology, 2003; 62: 362-367.

Glas AS, Roos D, Deutekom M ve ark. Tumor markers in the diagnosis primary bladder cancer: a systematic review. J Urol, 2003; 169: 1975-1982.

Hoque MO, Lee CC, Cairns P ve ark. Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nueleotide poly- morphism arrays and PCR-based microsatellite analysis. Cancer Res, 2003; 63: 2216-2222.

Hoque MO, Lee J, Begum S ve ark. High-throughput molecular analysis of urine sediment for the detection of bladder cancer by high-density single nueleotide polymorphism array. Cancer Res, 2003; 63: 5723- 5726.

Utting M, Werner W, Dahse R ve ark. Microsatellite analysis of free tumor DNA in urine, serum and plasma of patients: a minimally invasive method for the detection of bladder cancer. Clin Cancer Res, 2002; 8: 35-40.

Duesberg P, Rausch C, Rasnick D ve ark. Genetic instability of caneer cells is proportional to their degree of aneuploidy. Proc Natl Acad Sci USA, 1998; 95: 13692.

Jiang F, Caraway NP, Sabichi AL ve ark. Centresomal abnormality is common in and a potential biomarker for bladder cancer. Int J Cancer, 2003; 106: 661-665.

Halling KC, King W, Sokolova IA ve ark. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol, 2000; 164: 1768-1775.

Kelsey KT, Hirao T, Schned A ve ark. A population- based study of immunohistochemical detection of p53 alteration in bladder cancer. Br J Cancer, 2004; 90: 1572-1576.

Cordon-Cardo C. p53 and RB: simple interesting correlates or tumor markers of critical predictive nature? J Clin Oncol, 2004; 22:975-977.

Puig P, Capodieci P, Drobnjak M ve ark. p73 Expression in human normal and tumor tissues: loss of p73alpha expression is assoeiated with tumor progression in bladder cancer. Clin Cancer Res, 2003; 9: 5642-5651.

Tuna B, Yörükoğlu K, Tüzel E, Güray M, Mungan U, Kırkalı Z. Expression of p53 and mdm2 and their significance in recurrence of superficial bladder cancer. Pathol Res Pract, 2003; 199: 323-328.

Maas S, Warskulat U, Steinhoff C ve ark. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status. Urology, 2004; 63:392-397.

Başakçı A, Kirkali Z, Tüzel E, Yörükoğlu K, Mungan MU, Sade M. Prognostic significance of estrogen receptor expression in superficial transitional cell carcinoma of the urinary bladder. Eur Urol, 2002; 41: 342-345.

Bol MG, Baak JP, van Diermen B ve ark. Proliferation markers and DNA content analysis in urinary bladder TaT1 urothelial cell carcinomas: identification of subgroups with low and high stage progression risks. J Clin Pathol, 2003; 56: 447-452.

Matsumoto K, Shariat SF, Casella R ve ark. Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy. J Urol, 2003; 170: 2246-2252.

Kamai T, Tsujii T, Arai K ve ark. Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res, 2003; 9: 2632-2641.

Eijan AM, Sandes EO, Riveros MD ve ark. High expression of cathepsin B in transitional bladder carcinoma correlates with tumor invasion. Cancer, 2003; 98: 262-268.

Kırkalı G, Tüzel E, Güler C, Gezer S, Kırkalı Z. Significance of Tissue laminin P1, elastase and fibronectin levels in transitional cell carcinoma of the bladder. Eur Urol, 2001; 39: 292-299.

Sugimoto S, Maass N, Takimoto Y ve ark. Expression and regulation of tumor suppressor gene maspin in human bladder caneer. Cancer Lett, 2004; 203: 209-215.

Kelloniemi E, Rintala E, Finne P ve ark. Tumor- associated trypsin inhibitor as a prognostic factor during follow-up of bladder cancer. Urology, 2003; 62: 249-253.

Vasala K, Paakko P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker in bladder cancer. Urology, 2003; 62: 952-957.

Shariat SF, Matsumoto K, Kim J ve ark. Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder. J Urol, 2003; 170: 985-989.

Slaton JW, Millikan R, Inoue K ve ark. Correlation ol metastasis related gene expression and relapse-free survival in patients with locally advaneed bladder cancer treated with cystectomy and chemotherapy. J Urol, 2004; 171: 570-574.

Hoskin PJ, Sibtain A, Daley FM ve ark. GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Br J Cancer, 2003; 89: 1290-1297.

Duggan B, Williamson K. Molecular markers for predicting recurrence, progression and outcomes of bladder cancer (do the poster boys need new posters?). Curr Opin Urol, 2004; 14: 277-286.

Sanchez-Carbayo M, Cordon-Cardo C. Applications of array technology: identification of molecular targets in bladder cancer. Br J Cancer, 2003; 89: 2172-2177.

Celis JE, Celis P, Ostergaard M ve ark. Proteomics and immunohistochemistry define some of the steps involved in the squamous differentiation of the bladder transitional epithelium: a novel strategy for identifying metaplastic lesions. Cancer Res, 1999; 59: 3003-3009.

Celis JE, Celis P, Palsdottir H ve ark. Proteomic strategies to reveal tumor heterogeneity among urothelial papillomas. Mol Cell Proteomics, 2002; 1: 269-279.

Ferguson RE, Selby PJ, Banks RE. Proteomic studies in urological malignancies. Contrib Nephrol, 2004; 141: 257-279.

Ge H, Liu Z, Church GM ve ark. Correlation between transcriptome and interactome mapping data from Saccharomyces cerevisiae. Nat Genet, 2001; 29: 482- 486.

Kırkalı Z, Tüzel E. Yüzeyel mesane tümörlerinde Av- rupa Kanser Araştırma ve Tedavi Derneği (EORTC) Deneyimi. Hemato-Onkoloji, 2004; 6: 47-50.

Kırkalı Z, Tüzel E. Yüzeyel mesane kanserinde teda- vi. Hemato-Onkoloji 2004; 6: 42-46.

Mungan MU, Canda AE, Tüzel E, Yörükoğlu K, Kır- kalı Z. Risk factors for mucosal prostatic involvement in superficial transitional cell carcinoma of the bladder. Eur Urol, 2005; 48:760-763.